Your browser is no longer supported. Please, upgrade your browser.
Settings
MDVN Medivation, Inc. daily Stock Chart
MDVN [NASD]
Medivation, Inc.
Index- P/E28.52 EPS (ttm)3.14 Insider Own1.10% Shs Outstand81.69M Perf Week-0.19%
Market Cap7.31B Forward P/E21.68 EPS next Y4.13 Insider Trans-5.16% Shs Float80.76M Perf Month-16.57%
Income264.90M PEG- EPS next Q0.63 Inst Own94.60% Short Float3.84% Perf Quarter-22.85%
Sales780.10M P/S9.38 EPS this Y670.20% Inst Trans2.50% Short Ratio2.59 Perf Half Y-29.54%
Book/sh6.66 P/B13.44 EPS next Y77.75% ROA31.30% Target Price137.79 Perf Year-2.14%
Cash/sh6.09 P/C14.70 EPS next 5Y- ROE62.40% 52W Range80.01 - 141.58 Perf YTD-10.11%
Dividend- P/FCF30.63 EPS past 5Y42.20% ROI44.40% 52W High-36.22% Beta1.11
Dividend %- Quick Ratio2.60 Sales past 5Y59.30% Gross Margin- 52W Low12.86% ATR5.49
Employees485 Current Ratio2.60 Sales Q/Q18.60% Oper. Margin37.10% RSI (14)42.09 Volatility5.07% 5.23%
OptionableYes Debt/Eq0.28 EPS Q/Q-48.30% Profit Margin34.00% Rel Volume1.40 Prev Close89.54
ShortableYes LT Debt/Eq0.00 EarningsAug 06 AMC Payout0.00% Avg Volume1.20M Price90.30
Recom1.90 SMA20-4.57% SMA50-12.35% SMA200-20.41% Volume394,391 Change0.85%
Sep-03-15Initiated Citigroup Neutral
Aug-25-15Reiterated UBS Buy $145 → $148
Jul-30-15Reiterated Stifel Buy $146 → $107
Jun-04-15Reiterated Maxim Group Buy $155 → $168
May-08-15Reiterated UBS Buy $130 → $142
May-08-15Reiterated Maxim Group Buy $126 → $155
Apr-20-15Downgrade Credit Suisse Outperform → Neutral
Apr-08-15Reiterated Canaccord Genuity Buy $132 → $180
Mar-30-15Reiterated Maxim Group Buy $126 → $163
Mar-27-15Reiterated Barclays Overweight $133 → $150
Mar-25-15Reiterated Brean Capital Buy $125 → $142
Mar-02-15Reiterated Maxim Group Buy $118 → $126
Feb-26-15Reiterated Brean Capital Buy $118 → $125
Jan-29-15Reiterated Stifel Buy $112 → $128
Jan-23-15Initiated RBC Capital Mkts Sector Perform $100
Dec-15-14Reiterated UBS Buy $110 → $125
Sep-18-14Upgrade Canaccord Genuity Hold → Buy $60 → $132
Sep-12-14Reiterated Chardan Capital Markets Buy $100 → $122
Sep-11-14Reiterated Stifel Buy $89 → $112
Aug-08-14Reiterated UBS Buy $85 → $90
Aug-27-15 12:57PM  Medivation, Inc. Earnings Q2, 2015
09:30AM  The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure
Aug-25-15 05:00PM  Medivation to Gain Global Rights to BioMarin's Talazoparib
12:54PM  BioMarin's Medivation Deal Boosts EPS at Barrons.com
12:20AM  Two Bay Area drug companies cut half-billion-dollar cancer drug deal at bizjournals.com
Aug-24-15 10:22AM  Medivation Buying Breast-Cancer Drug From BioMarin at Investor's Business Daily -6.99%
07:49AM  Medivation buying rights to BioMarin cancer drug
07:07AM  MEDIVATION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial
07:00AM  Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin Marketwired
07:00AM  Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin GlobeNewswire
Aug-21-15 01:15PM  Why Medivation is a Stunning Biotech Opportunity
Aug-14-15 01:04PM  MEDIVATION, INC. Financials
Aug-08-15 08:10PM  10-Q for Medivation, Inc. at Company Spotlight
Aug-07-15 01:50PM  Medivation Tops Q2 Earnings & Ups View, Xtandi Impresses - Analyst Blog
08:03AM  Edited Transcript of MDVN earnings conference call or presentation 6-Aug-15 8:30pm GMT
Aug-06-15 07:00PM  Medivation tops Street 2Q forecasts -6.25%
04:30PM  Medivation Inc Earnings Call scheduled for 4:30 pm ET today
04:17PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:10PM  Medivation Reports Second Quarter 2015 Financial Results Marketwired
07:07AM  Q2 2015 Medivation Inc Earnings Release - After Market Close
Jul-31-15 01:34PM  Insight Into Earnings Is Sending Medivation, Inc. Shares Soaring Today at Motley Fool +8.62%
06:22AM  MEDIVATION, INC. Files SEC form 8-K, Other Events
Jul-29-15 04:41PM  Trending Now: MDVN -8.39%
Jul-16-15 04:10PM  Medivation Announces Second Quarter 2015 Financial Results Teleconference on August 6, 2015 Marketwired
Jul-13-15 12:19PM  Medivation (MDVN) Stock Falling After Earnings Estimates Cut at TheStreet
Jul-11-15 07:03AM  Why Shares in Medivation Inc. Tumbled Over 10% in June at Motley Fool
Jul-10-15 07:25AM  Biotech Investors That Own This Name Could See 50 Percent Near Term Upside, After Selloff
Jul-04-15 01:02PM  3 Biotech Stocks That Could Grow Faster than Apple at Motley Fool
Jun-29-15 07:00AM  Medivation Voted Three Years in a Row Among Top Workplaces in the San Francisco Bay Area Marketwired
Jun-19-15 04:08PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Se
07:30AM  Medivation to Redeem Outstanding Convertible Notes Due 2017 Marketwired
Jun-17-15 07:00AM  Medivation and Astellas Announce Enrollment of the First Patients in Advanced Prostate Cancer Outcomes Registry Marketwired
Jun-01-15 05:00PM  New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Meeting PR Newswire
05:00PM  New Enzalutamide Data in Triple-Negative Breast Cancer Presented at the 2015 American Society of Clinical Oncology Annual Meeting Marketwired
May-29-15 08:16AM  ASCO targets war on cancer
May-28-15 04:20PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers
04:10PM  Medivation Names Andrew Powell General Counsel Marketwired
May-21-15 02:43PM  Polaris: Our formula works
May-17-15 12:48PM  Medivation and Astellas Announce New Enzalutamide Data Presented at the 2015 American Urology Association Annual Meeting Marketwired
12:48PM  Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting PR Newswire
May-14-15 07:00AM  New Enzalutamide Data in Triple-Negative Breast Cancer to Be Presented at the 2015 ASCO Annual Meeting Marketwired
07:00AM  Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be Presented at 2015 ASCO Annual Meeting PR Newswire
May-09-15 08:09PM  10-Q for Medivation, Inc. at Company Spotlight
May-08-15 03:00PM  Medivation (MDVN) Misses on Q1 Earnings, Revenues - Analyst Blog
09:20AM  4 Pharmaceutical Companies Leading the Breast Cancer Fight at 24/7 Wall St.
07:45AM  Medivation (MDVN) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
May-07-15 06:43PM  Medivation, Jazz Q1 Reports Miss; Regeneron Beats at Investor's Business Daily
05:28PM  Medivation reports 1Q loss
05:08PM  Medivation Reports First Quarter 2015 Financial Results at noodls
04:15PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:10PM  Medivation Reports First Quarter 2015 Financial Results Marketwired
07:07AM  Q1 2015 Medivation Inc Earnings Release - After Market Close
May-05-15 07:20AM  New Enzalutamide Data to Be Presented in Late Breaking Plenary Session at AUA Annual Meeting at noodls
07:00AM  New Enzalutamide Data to Be Presented in Late Breaking Plenary Session at AUA Annual Meeting Marketwired
07:00AM  Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting PR Newswire
12:19AM  Medivation Announces Participation at Upcoming Investor Conference at noodls
May-04-15 04:10PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired
Apr-28-15 07:32AM  3 Biotech Stocks With Rising Short Interest
Apr-23-15 05:00PM  Medivation Announces First Quarter 2015 Financial Results Teleconference on May 7, 2015 at noodls
04:10PM  Medivation Announces First Quarter 2015 Financial Results Teleconference on May 7, 2015 Marketwired
Apr-20-15 07:10AM  Credit Suisse: Medivation 'Headwinds Loom'
06:35AM  Medivation downgraded by Credit Suisse
Apr-14-15 11:41AM  Two Biotech Buyout Candidates at Barrons.com
Apr-06-15 04:26PM  Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog
Apr-03-15 11:35AM  Xtandi Beats Casodex, Set to Top Zytiga at Barrons.com
Apr-02-15 10:32AM  Medivation's Xtandi Beats Casodex In Cancer Trial at Investor's Business Daily
07:00AM  Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In Strive Trial PR Newswire
07:00AM  Enzalutamide Demonstrates Statistically Significant Improvement in Progression Free Survival Compared With Bicalutamide in Strive Trial Marketwired
Mar-31-15 10:54AM  Biotech: Why It's Not a Bubble at Barrons.com
Mar-26-15 03:35PM  3 Biotech Stocks Bucking Short Interest Trends
03:20PM  Medivation-Astellas' Xtandi Positive in Prostate Cancer Study - Analyst Blog
Mar-25-15 10:36AM  Brean Capital Reiterates Buy Rating, Raises PT On Medivation As Xtandi Deserves To Move Upstream
Mar-24-15 07:37PM  ASTELLAS AND MEDIVATION ANNOUNCE NEW ENZALUTAMIDE DATA PRESENTED DURING PLENARY PRESENTATIONS AT THE 2015 EUROPEAN ASSOCIATION OF UROLOGY CONGRESS (pdf 110 KB) at noodls
07:09AM  Medivation and Astellas Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress at noodls
07:00AM  Medivation and Astellas Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress Marketwired
07:00AM  Astellas and Medivation Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress PR Newswire
Mar-19-15 06:00PM  Qorvo, Allegiant Among Few Top Stocks In Buy Range at Investor's Business Daily
Mar-18-15 09:30AM  Zacks Industry Outlook Highlights: Orexigen, MannKind, Amgen, Medivation and Express Scripts - Press Releases
Mar-16-15 04:32PM  New Enzalutamide Data to Be Presented in Late Breaking News Plenary Session at European Association of Urology Congress at noodls
04:10PM  New Enzalutamide Data To Be Presented In Late Breaking News Plenary Session At European Association Of Urology Congress PR Newswire
04:10PM  New Enzalutamide Data to Be Presented in Late Breaking News Plenary Session at European Association of Urology Congress Marketwired
Mar-11-15 08:22AM  Wedbush Securities Reiterates Outperform, Raises PT On Medivation On Increased International Estimates
Mar-10-15 05:51PM  New High Analysis: 2 Orphan Drugmakers Stay Strong at Investor's Business Daily
Mar-05-15 04:02PM  Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst +5.02%
Mar-03-15 11:44PM  Johnson & Johnson's Zytiga May Get a Boost at Barrons.com
Feb-27-15 07:08PM  10-K for Medivation, Inc. Company Spotlight
05:44PM  Four Hot Stocks You'll Want To Keep On Your Radar at Investor's Business Daily
09:31AM  Medivation (MDVN) Shares March Higher, Can It Continue? - Tale of the Tape
06:47AM  Can anything slow Medivation?
Feb-26-15 03:45PM  Growth-stock breakouts mean opportunity for speculators at MarketWatch +5.18%
12:12PM  Nasdaq, S&P 500 Hang Tough; Avago, Akorn Big Earnings Winners at Investor's Business Daily
11:20AM  Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog Zacks
10:20AM  Medivation Beats on Q4 Earnings & Revenues; Xtandi Soars - Analyst Blog Zacks
09:56AM  Medivation Tops Q4 Views On Strong Xtandi Results at Investor's Business Daily
Feb-25-15 07:15PM  Medivation beats Street 4Q forecasts AP
04:30PM  Medivation Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:24PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:10PM  Medivation Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update Marketwired
02:59PM  Stocks Mixed; United Therapeutics Jumps To New High at Investor's Business Daily
07:07AM  Q4 2014 Medivation Inc Earnings Release - After Market Close CCBN
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company's prostate cancer clinical trials include STRIVE, which is in Phase II clinical trial; PROSPER and EMBARK for which enrollment is ongoing for the Phase III clinical trial; PLATO, which is in the Phase IV clinical trial; AFFIRM and PREVAIL that have completed enrollment for the Phase III clinical trial; and TERRAIN for which enrollment is completed for the Phase II clinical trial. Its breast cancer clinical trials comprise AR+, TNBC, ER+ or PgR+ and HER2 Normal, and AR+ HER2 Amplified that are in Phase II clinical trials. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and License and Manufacturing and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. The company is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Machado Clarence PatrickDirectorJun 04Option Exercise9.3936,000337,86067,500Jun 08 06:25 PM
Machado Clarence PatrickDirectorJun 04Sale117.4336,0004,227,47831,500Jun 08 06:25 PM
Bierly RickChief Financial OfficerMay 20Sale130.001,000130,00014,841May 20 06:40 PM
Bierly RickChief Financial OfficerMay 08Sale125.0038548,12515,841May 12 08:07 PM
Bierly RickChief Financial OfficerMay 05Sale125.001,615201,87516,226May 06 07:42 PM
Bierly RickChief Financial OfficerMay 04Sale124.702,170270,60417,841May 06 07:42 PM
Bierly RickChief Financial OfficerApr 15Option Exercise58.103,000174,30023,011Apr 16 05:31 PM
Bierly RickChief Financial OfficerApr 15Sale132.203,000396,60020,011Apr 16 05:31 PM
Rhodes Jennifer JGC & Corporate SecretaryMar 16Sale130.921,390181,97911,090Mar 17 05:37 PM
Rhodes Jennifer JGC & Corporate SecretaryMar 02Option Exercise47.482,00094,96014,480Mar 02 09:16 PM
Svoronos DawnDirectorMar 02Sale119.753,350401,16313,639Mar 04 09:22 PM
Rhodes Jennifer JGC & Corporate SecretaryMar 02Sale122.002,000244,00012,480Mar 02 09:16 PM
Hung DavidPresident and CEOMar 02Sale120.83100,89112,190,609760,977Mar 02 09:15 PM
FALBERG KATHRYN EDirectorFeb 27Buy117.6725,0002,941,68425,000Mar 02 09:13 PM
Rhodes Jennifer JGC & Corporate SecretaryFeb 26Option Exercise47.482,00094,96014,480Feb 27 04:56 PM
Rhodes Jennifer JGC & Corporate SecretaryFeb 26Sale119.293,089368,50211,391Feb 27 04:56 PM
Hung DavidPresident and CEOFeb 26Sale120.1219,1092,295,373861,868Feb 27 04:55 PM
Machado Clarence PatrickDirectorFeb 10Option Exercise9.3936,000337,86067,500Feb 12 04:21 PM
Machado Clarence PatrickDirectorFeb 10Sale103.8936,0003,739,98431,500Feb 12 04:21 PM
Rhodes Jennifer JGC & Corporate SecretaryFeb 04Sale100.8561061,5198,980Feb 06 07:03 PM
Hung DavidPresident and CEOFeb 04Sale100.483,190320,519861,868Feb 06 07:04 PM
Machado Clarence PatrickDirectorJan 27Option Exercise9.6336,000346,61367,500Jan 29 05:34 PM
Machado Clarence PatrickDirectorJan 27Sale105.3236,0003,791,39231,500Jan 29 05:34 PM
Hung DavidPresident and CEOJan 20Sale108.14100,00010,814,242865,058Jan 22 06:33 PM
Seely LynnChief Medical OfficerDec 19Option Exercise10.1831,340318,94991,194Dec 22 07:42 PM
Rhodes Jennifer JGC & Corporate SecretaryDec 03Sale113.00910102,8309,590Dec 04 04:54 PM
Machado Clarence PatrickDirectorDec 03Sale113.001,580178,54031,500Dec 04 04:53 PM
Hung DavidPresident and CEODec 03Sale113.005,420612,460965,058Dec 04 04:52 PM
Seely LynnChief Medical OfficerOct 22Option Exercise10.595,00052,92564,854Oct 23 06:54 PM
Seely LynnChief Medical OfficerOct 22Sale99.035,000495,14259,854Oct 23 06:54 PM
Seely LynnChief Medical OfficerOct 16Option Exercise10.595,00052,92564,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 16Sale93.975,000469,85059,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 15Option Exercise8.0024,346194,73784,200Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 15Sale89.1124,3462,169,36359,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerSep 18Option Exercise10.5925,000264,62584,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 18Sale99.8125,0002,495,15859,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 17Option Exercise8.4630,000253,80089,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 17Sale97.3630,0002,920,72759,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 09Option Exercise10.5920,000211,70079,022Sep 11 06:04 PM
Seely LynnChief Medical OfficerSep 09Sale94.6020,0001,892,01659,022Sep 11 06:04 PM